Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change $ Change
grade D $2.90 5.45% 0.15
AEZS closed up 5.45 percent on Friday, March 24, 2017, on 40 percent of normal volume. It ran into resistance at its 50 day moving average.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical AEZS trend table...

Date Alert Name Type % Chg
Mar 24 50 DMA Resistance Bearish 0.00%
Mar 24 Stochastic Buy Signal Bullish 0.00%
Mar 24 Lower Bollinger Band Walk Other 0.00%
Mar 24 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 23 Lower Bollinger Band Walk Other 5.45%
Mar 22 Stochastic Reached Oversold Other 7.41%
Mar 21 50 DMA Resistance Bearish 3.57%
Mar 21 Expansion Pivot Sell Setup Bearish Swing Setup 3.57%
Mar 20 Fell Below 50 DMA Bearish 0.00%
Mar 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%

Older signals for AEZS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company’s product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company’s products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.59
52 Week Low 2.35
Average Volume 242,415
200-Day Moving Average 3.4066
50-Day Moving Average 2.937
20-Day Moving Average 2.975
10-Day Moving Average 2.89
Average True Range 0.179
ADX 14.15
+DI 19.14
-DI: 21.48
Chandelier Exit (Long, 3 ATRs) 2.763
Chandelier Exit (Short, 3 ATRs) 3.187
Upper Bollinger Band 3.2041
Lower Bollinger Band 2.7459
Percent B (%b) 0.34
Bandwidth 0.154017